Gilead Sciences (GILD)
$66.69
0.10 (0.15%)
GILD Stock Quote Delayed 30 Minutes
Biggest Movers in Healthcare Stocks Now – EXAS CLDX CLVS HSP
Healthcare stocks finished down broadly 0.2% on Wall Street on Thursday. NASDAQ:EXAS, NASDAQ:CLDX, NASDAQ:CLVS, NYSE:HSP, NASDAQ:PCRX, NASDAQ:IPXL, NASDAQ:KERX, NASDAQ:QCOR, NASDAQ:ALNY, NASDAQ:AUXL, NASDAQ:AEGR, NYSE:EW, NYSE:CNC, NASDAQ:GILD, NASDAQ:THRX, NASDAQ:MASI, NYSE:CAH, NYSE:MD, NYSE:AGN, NYSE:PBH
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
83.62B
PE Ratio
190.54
EPS
0.35
Volume (Avg. Vol.)
4.21M
Day's Range
$66.01 - $66.93
52-Week Range
$62.07 - $87.86
Dividend & Yield
$3.00 (4.50%)
GILD Stock Predictions, Articles, and Gilead Sciences News
6 Biotechnology Stocks to Buy Now
The grades of six biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
Emerging Market Turmoil Gives Rally Frostbite
Emerging market turmoil and Apple stock's crash rule the headlines, but it's the ongoing earnings calendar that will eventually turn the stock market around.
Chart Predicts Top Biotech Is About to Break Out
It appears to be only a matter of time before Gilead Sciences (GILD) breaks to new highs.
The S&P’s Most Dramatic Performances of 2013 (And What They Taught Us)
We look at 2013's best and worst performers in the S&P 500, as well as what that might say about returns in 2014.
GILD: Get on While Biotech Remains Hot
The bulls seemingly are unwilling to cast off biotech. And among the sector's biggest stocks, Gilead Sciences (GILD) has the most appealing setup.
Trade of the Day: Gilead Sciences (GILD)
Use the low-volume atmosphere around the New Year’s holiday to establish positions at a discount.
Trade of the Day: Gilead Sciences (GILD)
This market is bullish, with a capital B, and call options are the way to trade it.
Rumor Could Give Traders Another Shot at a Top Biotech
Gilead Sciences' (GILD) sell-off on an unconfirmed report may provide a good entry point.
Must-Own Biotech Just Issued a New Buy Signal
Gilead Sciences is in a powerful bull channel with accumulation building. Get the target for GILD.
5 Best Closed End Funds to Buy
Check out these five great closed end funds that offer investors upside in today’s low-interest-rate environment:
Buying Gilead Sciences Under $66 Would Be a Steal
After a post-earnings pop, Gilead Sciences (GILD) could retrace to support.
Don’t Pass Up the Chance to Buy This Top Biotech at a Discount
The recent pullback is offering an opportunity to get Gilead Sciences (GILD) at a bargain price.
4 Healthcare Investments to Make Before October
With open enrollment in state health insurance exchanges set to kick off on Oct. 1, it’s a good time to revisit the ways investors can play the opportunity.
Top 6 Stocks to Buy for September
These stocks should weather the storms of political and economic instability.
3 Funds to Play the Healthcare Megatrend
Healthcare has been hot in 2013, but more importantly, it's set up to be a huge mover going forward thanks to several big trends. Here's how to get your piece.
Changing U.S. Demographics Mean a Decades-Long Healthcare Boom
The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs.
The Best and Worst Mutual Funds at 2013’s Midway Point
The biggest trends so far in 2013 include gains in U.S. and Japanese stocks and pain in emerging markets and gold. These mutual funds benefited -- or suffered -- the most from these trends.
5 ETFs Set to Soar in the Second Half of 2013
The best way to invest amid a cloudy outlook is longer-term and lower-risk. One of the easiest ways to take on that kind of strategy is to buy diversified ETFs.
4 High-Fliers That Could Crash-Land Soon
2013 has been a very good year for some high-profile companies. In fact, for a few of these stocks, this year has been a little too good.
